Adverum Biotechnologies Inc., of Redwood City, Calif., appointed Christopher J. Morrison vice president, process development.
Aravive Inc., of Houston, appointed Reshma Rangwala chief medical officer.
Atea Pharmaceuticals Inc., of Boston, appointed Polly Murphy to its board.
Aviceda Therapeutics, of Cambridge, Mass., appointed Chris Adams and Nancy K. Thomason to its board.
Haima Therapeutics LLC, of Cleveland, appointed Wolfgang Bergmeier to its scientific advisory board.
Immatics NV, of Tuebingen, Germany, appointed Eliot Forster to its board.
Kronos Bio Inc., of San Mateo, Calif., appointed Elena Ridloff to its board and chair of its audit committee.
Matinas Biopharma Holdings Inc., of Bedminster, N.J., appointed Natasha Giordano to its board and audit committee.
Miragen Therapeutics Inc., of Boulder, Colo., appointed Lee Rauch president and CEO.
Nextcure Inc., of Beltsville, Md., appointed John G. Houston to its board.
Partner Therapeutics Inc., of Lexington, Mass., appointed Edwin Rock chief medical officer.
Rhythm Pharmaceuticals Inc., of Boston, appointed Yann Mazabraud executive vice president, head of international, effective Oct. 5.
Rockwell Medical Inc., of Wixom, Mich., appointed Russell L. Skibsted executive vice president, chief financial officer and chief business officer.
Veracyte Inc., of South San Francisco, appointed Richard T. Kloos executive medical director.
Voyager Therapeutics Inc., of Cambridge, Mass., appointed Michelle Quinn Smith chief human resources officer.
Vtv Therapeutics Inc., of High Point, N.C., appointed Edward P. Taibi to its board.
Tizona Therapeutics Inc., of South San Francisco, appointed Christine O’Brien CEO.
Ziopharm Oncology Inc., of Boston, appointed Adi Barzel, Gavin Dunn, Matthew Porteus and Kole Roybal its scientific advisory board.